U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07056699) titled 'SGLT2i, Pioglitazone, and Ketone Production in T1D' on June 26.
Brief Summary: Participants are being asked to be in a research study. Scientists do research to answer important questions which might help change or improve treatment of participants disease in the future.
In patients with Type 1 Diabetes (T1D), Dapagliflozin a Selective Glucose Transporter 2 Inhibitor (SGLT2i) is known to increase production of glucose in the liver, increase breakdown of fats (lipolysis), and increase production of ketones (ketogenesis). Ketones are chemicals produced by the liver when the body breaks down fat for energy instead of glucose. When the...